The prevalence and disease burden of severe eosinophilic asthma in Japan
Open Access
- 2 November 2018
- journal article
- research article
- Published by Informa UK Limited in Journal of Asthma
- Vol. 56 (11), 1147-1158
- https://doi.org/10.1080/02770903.2018.1534967
Abstract
Background: There are limited data on the prevalence and burden of severe eosinophilic asthma (SEA) both in Japan and globally. This study aimed to assess the prevalence and burden of SEA in Japan. Methods: This study was a retrospective, observational cohort analysis using health records or health insurance claims from patients with severe asthma treated at Kyoto University Hospital. The primary outcome was the prevalence of SEA, defined as a baseline blood eosinophil count ≥300 cells/μL. Secondary outcomes included frequency and risk factors of asthma exacerbations, and asthma-related healthcare resource utilization and costs. Results: Overall, 217 patients with severe asthma were included; 160 (74%) had eosinophil assessments. Of these, 97cases (61%), 54cases (34%), and 33cases (21%) had a blood eosinophil count ≥150, ≥300, and ≥500 cells/μL, respectively. Proportion of SEA was 34%. Blood eosinophil count was not associated with a significantly increased frequency of exacerbations. In the eosinophilic group, lower % forced expiratory volume in 1 second and higher fractional exhaled nitric oxide were predictive risk factors, while the existence of exacerbation history was a predictive risk factor for asthma exacerbations in the non-eosinophilic group. Severe asthma management cost was estimated as ¥357,958/patient-year, and asthma exacerbations as ¥26,124/patient-year. Conclusions: Approximately, one-third of patients with severe asthma in Japan have SEA. While risk factors for exacerbations differed between SEA and severe non-eosinophilic asthma, both subgroups were associated with substantial disease and economic burden. From subgroup analysis, blood eosinophil counts could be an important consideration in severe asthma management.Keywords
Funding Information
- GSK (47/HO-15-)
This publication has 28 references indexed in Scilit:
- Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypesJournal of Allergy and Clinical Immunology, 2014
- Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthmaNature Medicine, 2013
- Asthma Control and Management Changes in Japan: Questionnaire SurveyInternal Medicine, 2012
- Consistency of sputum eosinophilia in difficult-to-treat asthma: A 5-year follow-up studyJournal of Allergy and Clinical Immunology, 2009
- Intrinsic asthma: not so different from allergic asthma but driven by superantigens?Clinical and Experimental Allergy, 2009
- Cluster Analysis and Clinical Asthma PhenotypesAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthmaThorax, 2007
- Asthma: defining of the persistent adult phenotypesThe Lancet, 2006
- “Refractory” Eosinophilic Airway Inflammation in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Asthma exacerbations and sputum eosinophil counts: a randomised controlled trialThe Lancet, 2002